Cancer immunotherapy developer Mustang Bio (NASDAQ: MBIO) has promoted Sadik Kassim to chief scientific officer. Kassim joined New York-based Mustang last year as vice president of process and analytical development. He came to Mustang from Novartis (NYSE: NVS), where he was head of analytical development. Mustang also promoted Knut Niss to chief technology officer. Niss joined the company last year as vice president of operations. He previously worked at Biogen (NASDAQ: BIIB) as cell therapy asset leader. Mustang’s pipeline includes two drugs in Phase 1 studies, MB-101 for glioblastoma and MB-102 for acute myeloid leukemia.